Calithera Biosciences Inc to Acquire Assets From Takeda Pharmaceutical Co Ltd Call Transcript
Ladies and gentlemen, thank you standing by, and welcome to the Calithera's business update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded. I would now like to turn the conference to your host, Stephanie Wong, CFO. Ma'am, you may begin.
Thank you, operator, and good afternoon, everyone. Welcome to our conference call to discuss our agreement with Takeda Pharmaceuticals to acquire 2 clinical-stage assets, sapanisertib and mivavotinib. Joining me today are Susan Molineaux, Founder, President and CEO; and Keith Orford, Chief Medical Officer. Earlier today, we issued a press release that included an overview of the transaction, which can be accessed through our website at calithera.com, alongside an updated corporate deck.
Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans that constitute forward-looking statements for the purposes of the safe harbor provisions of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
